Anticanceragent 308 (compound 3s) is an AKT inhibitor with antitumor activity. It reduces the total AKT protein levels, thereby inhibiting the prosurvival PI3K/AKT signaling pathway. Anticanceragent 308 induces apoptosis, disrupts mitochondrial membrane potential, promotes the accumulation of reactive oxygen species (ROS) in mitochondria, and causes cell cycle arrest. It can also inhibit cancer cell migration and is applicable for research in breast cancer, lung adenocarcinoma, cervical cancer, prostate cancer, and hepatocellular carcinoma.